BioCentury | Mar 25, 2020
Product Development

Repurposing candidates for COVID-19 from UCSF, Aldeyra

A UCSF team has keyed in on more than five dozen compounds against nearly as many targets that could be repurposed to target the virus behind COVID-19. Meanwhile, a repurposing screen by Aldeyra could yield...
BioCentury | Feb 25, 2020
Distillery Therapeutics

Inhibiting necroptosis to treat ischemic stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Preventing neuronal necroptosis by disrupting the interaction between ASIC1A, an acid-sensing ion channel, RIPK1 and NSF could treat ischemic stroke. During acidosis, the interaction between ASIC1A’s C- and N-termini is...
BioCentury | Feb 5, 2020
Product Development

Leaner GSK ups R&D investments in immunology, genetics

GSK has formally started the process of splitting its innovative R&D and consumer health businesses into two companies, while continuing to cull down its clinical pipeline. In its 4Q19 earnings Wednesday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)...
BC Innovations | Sep 13, 2019
Tools & Techniques

Getting higher-quality hits out of DNA-encoded libraries

DNA-encoded libraries are quickly surpassing traditional high throughput screens as industry’s first stop for hit generation. Now, developers are taking the technology up a notch to get more tractable hits in the output. DNA-encoded library...
BC Extra | Aug 5, 2019
Clinical News

Aug. 5 Clinical Quick Takes: Emgality meets for migraine with treatment failures; plus Verona, Alkahest-Grifols, Squarex and Denali-Sanofi

Emgality meets in Phase III in pretreated migraine patients  Eli Lilly and Co. (NYSE:LLY) reported that anti-CGRP mAb Emgality galcanezumab-gnlm met the primary endpoint in the Phase III CONQUER trial, reducing migraine headache days by...
BC Innovations | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
BC Innovations | Apr 11, 2019
Targets & Mechanisms

A venture view of biological white space

Scanning the horizon of translational research, VCs on BioCentury’s scientific advisory board see innate neuroinflammation as a white space area flush with under-tapped angles for drug development, and think the rise of single cell-level data...
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
BC Innovations | Nov 9, 2018
Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
BC Week In Review | Nov 2, 2018
Company News

Sanofi deal will bank roll Denali's indication expansion

Sanofi (Euronext:SAN; NYSE:SNY) paid Denali Therapeutics Inc. (NASDAQ:DNLI) $125 million in cash up front to co-develop multiple receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1) inhibitors to treat neurological and systemic inflammatory diseases. Sanofi will cover most...
Items per page:
1 - 10 of 35